Science:新方法有助于寻找罕见遗传病的病因

2019-10-14 佚名 细胞

近日,Scripps Research的科学家们发明了一种新的基因组技术,可用于追踪罕见遗传疾病的原因。

近日,Scripps Research的科学家们发明了一种新的基因组技术,可用于追踪罕见遗传疾病的原因。

研究人员在《Science》杂志上报告了这项技术。该技术利用了这样一个事实,即人体每个基因的两个拷贝,或“等位基因”,分别来自母亲与父亲。通过比较整个基因组中来自母本和父本的等位基因的活性水平,能够进一步分析疾病发生的原因。

在该研究中,科学家们通过使用这项技术揭示了罕见的肌营养不良患者的致病基因。

研究第一作者Pejman Mohammadi博士说:“这种方法可以使我们在某些标准检测手段无效的情况下找到罕见遗传病的原因。

Mohammadi等人开发的方法使用基因转录数据来检测母本和父本等位基因活性水平的差异。众所周知,许多罕见的遗传病是由影响基因单个拷贝的DNA突变引起的。因此,比较同一细胞内母本和父本等位基因的活性,相比不同患者以及健康人群体相关基因之间的活性比较更为敏感。

穆罕默迪说:“即使是同卵双胞胎,其中一个人早晨吃了一个汉堡,而另外一个人没有吃,他们的许多基因活性可能都存在差异”。

为了帮助评估等位基因的活动的异常,该方法根据可公开获得的基因转录数据计算每个基因的母体和父亲等位基因活性正常的差异范围。

该方法称为ANEVA-DOT(表达变异分析-剂量离群值测试),可用于鉴定每个个体中的少数几个基因的其中一个等位基因表达水平是否异常。

他和他的同事利用ANEVA-DOT方法检测一组患有肌营养不良型遗传病的患者,并得到了阳性的结果。

原始出处:Pejman Mohammadi, Stephane E. Castel, Beryl B. Cummings, et al.Genetic regulatory variation in populations informs transcriptome analysis in rare disease. Science, 2019; eaay0256 DOI: 10.1126/science.aay0256

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1968945, encodeId=2e2c196894535, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Jul 19 17:30:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903381, encodeId=66fd1903381c0, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Aug 29 22:30:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375988, encodeId=f24213e5988d6, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Oct 16 07:30:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467491, encodeId=0df2146e49129, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Oct 16 07:30:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1968945, encodeId=2e2c196894535, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Jul 19 17:30:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903381, encodeId=66fd1903381c0, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Aug 29 22:30:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375988, encodeId=f24213e5988d6, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Oct 16 07:30:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467491, encodeId=0df2146e49129, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Oct 16 07:30:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1968945, encodeId=2e2c196894535, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Jul 19 17:30:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903381, encodeId=66fd1903381c0, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Aug 29 22:30:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375988, encodeId=f24213e5988d6, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Oct 16 07:30:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467491, encodeId=0df2146e49129, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Oct 16 07:30:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
    2019-10-16 jichang
  4. [GetPortalCommentsPageByObjectIdResponse(id=1968945, encodeId=2e2c196894535, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Jul 19 17:30:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903381, encodeId=66fd1903381c0, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Aug 29 22:30:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375988, encodeId=f24213e5988d6, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Oct 16 07:30:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467491, encodeId=0df2146e49129, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Oct 16 07:30:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
    2019-10-16 syscxl

相关资讯

Cell Rep:新方法:寻找“长生不老药”

近日,来自瑞典卡罗林斯卡学院的研究人员开发出一种新的方法来鉴定抗衰老化合物,它基于一种新的测定人类细胞年龄的方法。通过这种方法,研究人员发现了一组他们预测能使人类细胞恢复活力的候选物质,这些物质延长了模式生物秀丽线虫的寿命,并改善了其健康状况。该研究近日已发表在《Cell Reports》上。

Sci Rep:瞬态波在膀胱非侵入性评价中的声弹性分析

最近,有研究人员展示了一种非侵入性的膀胱壁非线性弹性行为测量方法。他们的方法是基于不同体积应变水平时膀胱组织模量的弹性变化声弹性模型来进行的。在每一种体积下,组织应变水平通过实时的超声图像来获得。通过声辐射力,在膀胱壁上激发了一个瞬态兰姆波,通过对时空色散图的二维傅里叶分析,研究人员就能获得剪切弹性的瞬时模量。之后,测量的弹性和应变数据在声弹性公式中运用,从而获得三阶弹性系数,称为非线性参数A与初

NAT MED:新方法让科学家找到治愈艾滋病的关键

很多年前,提到艾滋病,人们都会觉得非常恐怖,因为艾滋病可以引起多种自身免疫病变,然而,随着抗逆转录病毒疗法的运用,艾滋病已经在很大程度上得到了控制。只要治疗得当,艾滋病不会对患者的正常生活造成过多的影响。

Cancer Cell亮点:洪明奇团队开发新方法提高PD-L1阳性检出率

近年来,免疫疗法已发展为癌症治疗的重要策略,而抗PD-1/PD-L1的癌症免疫疗法在经过诸多研究检视与临床试验后已广受认可,成为目前最主要的治疗方式之一,其在许多种癌症治疗上引领许多革命性的进展。

Sci Rep:基于脉冲调制AML光纤激光器的人体视网膜成像系统新方法

韩国光州科学技术研究院先进光子学研究所的Lee HD和韩国大学医学院眼科的Lee B等人近日在Sci Rep杂志上发表了一篇重要的研究论文,在这项研究中,他们将1080nm波长的脉冲调制AML光纤激光器作为OCT系统的动态扫描源,用于人体视网膜体内成像。

Sci Signal:科学家发现止痛新方法 有望降低药物耐受性和上瘾风险

美国科学家发现,沿两条化学途径(其中一条为先前发现的与大脑感觉“痒”相关的途径)激活神经细胞受体与常规使用阿片类药物(如吗啡等)钝化疼痛的方法相结合,可以改善缓解疼痛的效果。